These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

764 related items for PubMed ID: 27862809

  • 1. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

  • 3. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 5. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 6. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [Abstract] [Full Text] [Related]

  • 7. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA, OFSEP Investigators.
    JAMA Neurol; 2020 Jan 01; 77(1):94-102. PubMed ID: 31479149
    [Abstract] [Full Text] [Related]

  • 8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 9. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.
    PLoS One; 2017 May 17; 12(4):e0174858. PubMed ID: 28406921
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.
    Mult Scler; 2016 Aug 17; 22(9):1174-83. PubMed ID: 26564995
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
    Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.
    Expert Opin Drug Saf; 2017 Aug 17; 16(8):963-972. PubMed ID: 28641055
    [Abstract] [Full Text] [Related]

  • 12. Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
    Lo Buono V, D'Aleo G, Cammaroto S, De Cola MC, Palmese F, Smorto C, Marino S, Venuti G, Sessa E, Rifici C, Corallo F.
    Medicina (Kaunas); 2022 Apr 17; 58(4):. PubMed ID: 35454389
    [Abstract] [Full Text] [Related]

  • 13. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 14. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 17; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 15. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E.
    J Neurovirol; 2017 Oct 17; 23(5):734-741. PubMed ID: 28831768
    [Abstract] [Full Text] [Related]

  • 16. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud MA, Duhin E, Verclytte S, Zins M, Luciani A, Rahmouni A, Pruvo JP, Vermersch P, Leclerc X.
    Radiology; 2016 Mar 17; 278(3):863-72. PubMed ID: 26436861
    [Abstract] [Full Text] [Related]

  • 17. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun 17; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

  • 18. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X.
    Rev Neurol; 2015 Feb 16; 60(4):164-8. PubMed ID: 25670046
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 16; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 20. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 16; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.